Unique Research Funding Strategy
Cure Alzheimer’s Fund (CAF) takes a venture capital approach to medical research by finding the visionaries in the field, supporting them, focusing on the essentials by establishing a frugal culture and daring to be great. Our research objective is to support the scientists doing the most innovative work that will move knowledge of Alzheimer’s pathology most expeditiously to prevention and cure.
Our research follows a Research Roadmap designed by leading Alzheimer’s researchers who form the CAF Research Consortium. Proposals typically arise from members of the Consortium for their own work or complementary projects with or by others. Proposals are brief, with an emphasis on objectives, proposed outcomes, method and supporting data. They are reviewed by the chair of our Research Consortium and then by members of the Scientific Advisory Board. No scoring rubric is used; rather, questions or concerns are related to the researcher, who then may modify or explain the proposal accordingly. Mid-year and final reports are required. With sufficient reason to continue, some projects may be funded beyond one year. We do not accept unsolicited proposals, nor do we fund indirect costs or overhead at host institutions. Approval usually takes about two weeks, with funds delivered to the host institution within three weeks.
Latest Research Updates
Posted: Jan. 8, 2014
A stem cell model of familial Alzheimer’s disease (FAD) was successfully generated in a recent study, allowing researchers to identify 14 genes potentially implicated in the disease. One gene in particular demonstrates the important role inflammation may play in the brain of Alzheimer’s patients. The study was completed by scientists at The New York Stem Cell Foundation (NYSCF) Research Institute in collaboration with scientists at the Icahn School of Medicine at Mount Sinai (ISMMS) and funded in part by the Cure Alzheimer’s Fund (CAF).
Posted: Jan. 8, 2014
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute, working in collaboration with scientists from Columbia University Medical Center (CUMC), for the first time generated induced pluripotent stem (iPS) cells lines from non-cryoprotected brain tissue of patients with Alzheimer’s disease.
Posted: Dec. 19, 2013
Brain aging is associated with lower production of circadian clock proteins, which synchronize biological processes to light and dark cycles. In Alzheimer’s and other neurodegenerative diseases, circadian dysfunction is commonly observed.
Posted: Sep. 20, 2013
In a paper just published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.
Posted: Jul. 29, 2013
For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.